Pharmaceutical scientists involved with APS
Who We Are
The Academy of Pharmaceutical Sciences (APS) is the UK-based professional membership body for Pharmaceutical Scientists.
We represent individuals and organisations from around the globe, throughout their development, in the delivery of excellence in the Pharmaceutical Science sector.
Pharmaceutical Scientists are experts in the research, development and manufacture of medicines. They have a major role in the regulation of medicines and understanding their use in patients.
What We Do
The APS is a not-for-profit organisation. We use revenues to champion innovation and opportunity in Pharmaceutical Sciences thereby improving the development and delivery of medicines for the benefit of patients. Our four key strategic themes, which are the foundation of all APS activities, are:
- Establish and promote the reputation of Pharmaceutical Sciences and Scientists
- Influence policy
- Further scientific knowledge
- Promote careers
Board Roles & Responsibilities
Each member on the board and advisory board is
responsible for a specific area of development
Board Meetings 2021- 21st January, 18th March, 29th April, 17th June, 9th September & 18th November.
APS Priorities for 2021
- Promote and enhance diversity across our membership, board and fellows
- Enhance and communicate the value of APS membership
- Deliver a successful PharmSci 2021 virtual conference Autumn event for our members
- Deliver multiple webinars through 2021 for our members to include repeat of our successful develop ability training event and virtual Industrial Insights for students
- Provide a vibrant Focus Group community for our members, with new groups aligned with current scientific areas
- Support and grow our accredited institution community
The APS Board
The APS Board
Jo is a Pharmacist and has spent her entire career working in the pharmaceutical industry with a focus on pharmaceutical development, product quality and the introduction of new manufacturing technologies. She is currently Senior Vice President CMC (Chemistry Manufacturing & Controls) for two clinical stage biotech companies, NeRRe and KaNDy Therapeutics, located at the Stevenage Biosciences Catalyst, a role she has held since Summer 2018. Previously, Jo spent over 30 years at GlaxoSmithKline where her career spanned many leadership roles in CMC product development, most recently as Vice President of Technology & Strategy, Product Development & Supply. Jo continues to be involved with the Medicines Manufacturing Industry Partnership (MMIP) where she has been influential in aligning Pharma and UK Government on future areas for investment. Jo is an Eminent Fellow of the Academy of Pharmaceutical Sciences, UK and has been an Advisor to the APS Board for several years.
Dr Mark McAllister is a Senior Scientific Director in the Drug Product Design group at Pfizer (Sandwich) with responsibility for mid-to-late stage development projects. He is a Pharmacy graduate from Queen’s University Belfast and has a pharmaceutics PhD from Aston University. Mark has over 20 years industrial development experience and has specialised in oral delivery systems and biopharmaceutics. He is the current chairman of the Academy of Pharmaceutical Sciences, APS biopharmaceutics focus group leader and a fellow of the Royal Pharmaceutical Society. Mark co-leads the IMI ‘OrBiTo’ project, an academic/industrial collaboration, developing the next generation of models to predict oral absorption.
Professor Ryan Donnelly holds the Chair in Pharmaceutical Technology at Queen’s University Belfast and is Director of QUB’s interdisciplinary research programme Materials & Advanced Technologies for Healthcare (MATCH). His personal research is centred on design and physicochemical characterisation of advanced polymeric drug delivery systems for transdermal and intradermal drug delivery, with a strong emphasis on improving patient outcomes. He is currently developing a range of novel microneedle technologies through independent research, but also in collaboration with several major pharma partners. He has obtained substantial UK Research Council, charity and industrial funding and authored over 300 peer-reviewed publications (H-index = 58), including 6 patent applications, 6 textbooks, 23 book chapters and approximately 250 full papers. He has been an invited speaker at numerous national and international conferences. Professor Donnelly is Europe/Africa Editor of Drug Delivery & Translational Research and the Controlled Release Society’s Communications Chair. He has won the Academy of Pharmaceutical Science’s Innovative Science Award (2020), Evonik’s Resomer Award (2018), the Controlled Release Society’s Young Investigator Award (2016), BBSRC Innovator of the Year and the American Association of Pharmaceutical Scientists Pharmaceutical Research Meritorious Manuscript Award (2013), the GSK Emerging Scientist Award (2012) and the Royal Pharmaceutical Society’s Science Award (2011).
Dr Hannah Batchelor Is a senior Lecturer in Pharmaceutics, Formulation and Drug Delivery at the University of Birmingham.
Hannah is a pharmaceutical scientist who has worked in academia, the NHS and within pharmaceutical industry. Her research interests lie in the optimisation of drug formulations to maximise their biopharmaceutical performance and acceptability to children. Her research is informed by the views of children, young people and parents to ensure that the patients are at the centre of new developments.
She has been invited to present at many National and International scientific meetings as well as a TED talk.
Hannah is a pharmaceutical scientist who has worked in academia, the NHS and within pharmaceutical industry. Her research interests lie in the optimisation of drug formulations to maximise their biopharmaceutical performance and acceptability to children. Her research is informed by the views of children, young people and parents to ensure that the patients are at the centre of new developments.
She has been invited to present at many National and International scientific meetings as well as a TED talk.
M.B. Delgado Charro graduated in Pharmacy, received a PhD in Pharmaceutical Technology, and was a MEC-Fulbright fellow & visiting Assistant Professor at UCSF (1991-1993). She has worked as an academic at the Universities of Santiago de Compostela and Geneva, and since 2004, at the University of Bath where she is currently a Reader. She was a National Expert on Secondment at the European Medicines Agency (10/2015-9/2016) where she worked in business intelligence in drug development and Road-to-Market analysis.
Dr Delgado-Charro research focuses on transdermal and topical drug delivery, the development of optimized methods to treat and prevent nail diseases, non-invasive sampling for drug monitoring and pharmacokinetics, and the assessment of topical bioavailability and bioequivalence. Her work has been funded by several private and public sponsors and her scholastic work (Scopus author ID: 7003434711) includes 105 peer-reviewed scientific articles, 10 book chapters, and several patent applications. Her academic work focuses on the areas of pharmacokinetics and pharmaceutics in the frame of Pharmacy and Pharmacology degrees.
Dr Delgado-Charro research focuses on transdermal and topical drug delivery, the development of optimized methods to treat and prevent nail diseases, non-invasive sampling for drug monitoring and pharmacokinetics, and the assessment of topical bioavailability and bioequivalence. Her work has been funded by several private and public sponsors and her scholastic work (Scopus author ID: 7003434711) includes 105 peer-reviewed scientific articles, 10 book chapters, and several patent applications. Her academic work focuses on the areas of pharmacokinetics and pharmaceutics in the frame of Pharmacy and Pharmacology degrees.
Dr Bahijja Raimi-Abraham is a pharmacist, Lecturer in Pharmaceutics at King’s College London and Founder of King’s College London Fight the Fakes and Academic Lead. She leads her research group “The Raimi-Abraham Group”. Her research to date has been in pharmaceutical materials and innovative manufacture. More recently she has focused her research efforts within the therapeutic and drug development aspects of malaria.
Prior to her current position as Lecturer in Pharmaceutics at King’s College London, Dr. Raimi-Abraham held positions at University College London (UCL) as an Engineering and Physical Sciences Research Council (EPSRC) postdoctoral researcher position and at the European Medicines Agency (EMA) as a seconded Quality National Expert.
Dr. Raimi-Abraham is the first graduate of the University of East Anglia School of Pharmacy to be awarded a Ph.D. and more recently won the Outstanding Woman in STEM Precious Award.
Dr Raimi-Abraham has an extensive and original public engagement portfolio which includes uniquely exploring the use of street art to engage public with Science, Technology, Engineering and Mathematics (STEM) research through her social enterprise STEAM:ED Collective, a TEDx talk (TEDx Talk title “Elements of Change: Becoming an Independent Researcher) and a “Go and No-go pills” Somerset House 24/7 exhibition, visited by ~35,000 people (Oct. 2019 – Feb. 2020)). More recently hosting a weekly podcast, Monday Science which discusses the latest in Science, Health and Technology. Dr Raimi-Abraham’s work in research informed teaching has also been recognised by the Nuffield Foundation.
Geoff is CEO of Bionow the membership organisation for life science businesses in the North of England. Prior to this Geoff was founder and Technical Director of Biorite Ltd and Advanced Biomedical Ltd both spin-out companies from the University of Manchester. Geoff has a degree in Biochemistry and a PhD from the School of Pharmacy, University of Manchester where he began his career undertaking postdoctoral research.
Julie is Director, Product Development at AstraZeneca R&D.
Bob Clay established his regulatory consultancy practice through Highbury Regulatory Science in 2014 which supports small/medium size companies and their investors to develop regulatory/business strategies across multiple therapeutic and geographic areas. Before this, he was a VP of Global Regulatory Affairs at AstraZeneca with responsibility for oncology, infection, and personalised healthcare. He is a member of the Expert Scientific Advisory Committee for Medicines for Malaria Venture (MMV) and works with several, not for profit organisations involved in global health initiatives. He was a board member of TOPRA (The Organisation of Professional Regulatory Affairs) from 2014 – 2018, and President for 2017.
Bob is a pharmacist with more than 30 years’ experience in drug development, leading the global regulatory approval of many products across a range of therapy areas including metabolic diseases, neuroscience, cancer, and infection, involving more than 15 new substances. Earlier in his career, he was a formulation scientist and pharmaceutical reviewer at UK regulatory agency. Bob has held significant leadership roles in regulatory affairs in regional and global functions at several companies including AstraZeneca and Pfizer and served as Chief Regulatory Officer at Kinapse (2014-2017).
Bob is a pharmacist with more than 30 years’ experience in drug development, leading the global regulatory approval of many products across a range of therapy areas including metabolic diseases, neuroscience, cancer, and infection, involving more than 15 new substances. Earlier in his career, he was a formulation scientist and pharmaceutical reviewer at UK regulatory agency. Bob has held significant leadership roles in regulatory affairs in regional and global functions at several companies including AstraZeneca and Pfizer and served as Chief Regulatory Officer at Kinapse (2014-2017).
The Advisory Board
The Advisory Board
Linda has more than 40 years’ experience in the pharmaceutical industry, having worked for companies such as Glaxo, Marion Merrell Dow, Celltech, Eli Lilly, Schwarz Pharma AG and UCB Biosciences. Her experience covers pharmaceutical development, preclinical development, clinical trial supplies, quality assurance and project leadership. Since 2016 Linda has been an independent consultant with a focus on pharmaceutical development and development strategy.
Linda is a Vice President of FIP (International Pharmaceutical Federation), a member of the Assembly of Royal Pharmaceutical Society (RPS) and the immediate past Chairman of the Academy of Pharmaceutical Sciences. She is also visiting Professor at Sunderland University and is eligible to be a Qualified Person. Linda is a Fellow of both the Royal Pharmaceutical Society and FIP.
Linda is a Vice President of FIP (International Pharmaceutical Federation), a member of the Assembly of Royal Pharmaceutical Society (RPS) and the immediate past Chairman of the Academy of Pharmaceutical Sciences. She is also visiting Professor at Sunderland University and is eligible to be a Qualified Person. Linda is a Fellow of both the Royal Pharmaceutical Society and FIP.
Trevor is a Board member of the life sciences investment company Arix Bioscience plc; and the Oxford based Drug Discovery Company, e-Therapeutics. He was a Director of Allergan Inc. (USA), R&D Director of The Wellcome Foundation and Director General of The ABPI.
He holds honorary degrees and Gold Medals from 7 universities; is a founder member of Medicines for Malaria Venture (MMV); member of The UK Government Regulatory Agency, The Medicines Commission; advisor to the Cabinet Office on the Human Genome project; Chair of the UK Government Advisory Group on Genetics Research; member of the Wales Government Bevan Commission on health; advised the Government of the Netherlands TiPharma on Life Science and is a member of the EU Commission IMI Scientific Advisory Board.
He holds honorary degrees and Gold Medals from 7 universities; is a founder member of Medicines for Malaria Venture (MMV); member of The UK Government Regulatory Agency, The Medicines Commission; advisor to the Cabinet Office on the Human Genome project; Chair of the UK Government Advisory Group on Genetics Research; member of the Wales Government Bevan Commission on health; advised the Government of the Netherlands TiPharma on Life Science and is a member of the EU Commission IMI Scientific Advisory Board.
Mike is Managing Director of the East Midlands Academic Health Science Network (AHSN), an NHS organisation charged with transforming the health of 4.6 million people living in the East Midlands and stimulating wealth creation in the region. Mike joined the NHS after 28 years developing new medicines. Mike has managed and contributed to the development of the formulations, devices, drug substance manufacturing processes and associated test methods for a number of innovative new medicines.
As a member of the Advisory Board Mike supports the board in developing strategies that promote the pharmaceutical sciences and encourage high standards of practice.
As a member of the Advisory Board Mike supports the board in developing strategies that promote the pharmaceutical sciences and encourage high standards of practice.
Bill Dawson is a previous Chair of APS and is now an Advisory Board member with responsibility for the accreditation process. His career was primarily in industry, mostly as Research Director for Eli Lilly and Co in the UK but has been an academic and a community pharmacist. Currently he runs a health care consultancy advising universities and SMEs on development and commercialisation of new medicines and devices. He is a visiting professor at the universities of Durham and Nottingham and is an external adviser to Stevenage Bioscience Catalyst, an open innovation campus.
Currently I am Pro-Vice-Chancellor (Education and Students) and Professor of Biomaterials Science at Queen’s University Belfast. As an internationally renowned pharmaceutical/biomedical engineer my research seeks to provide engineering solutions to medical and pharmaceutical problems. These include innovations in the design of drug containing implants and medical devices to that reduce the morbidity and mortality associated with medical device related infection. Commercialisation of this research has occurred and is ongoing. Within the pharmaceutical domain, I have developed novel implants for the treatment of local diseases and, additionally, engineering technologies to develop new dosage forms, including strategies in which drugs of low solubility (negating their clinical utility) may be developed for clinical usage.
John Wahlich is a chemist with over 40 years’ experience in Pharmaceutical Development gained with a number of major pharmaceutical companies. He obtained his BSc from Bristol University and his PhD (part-time) from University of Nottingham School of Pharmacy. Until November 2010 he was a Vice President in GlaxoSmithKline and ran various multi-national departments involved with analytical chemistry, Product Line Extension development, physical properties and developability and early stage CMC support. He has a good knowledge of Quality by Design, Change Control and Technology Transfer. He is currently CEO of John Wahlich Associates Ltd a consulting company specialising in the pharmaceutical sciences. John is currently consulting for a number of companies on early stage product development. He is an Advisory Board member of the UK Academy of Pharmaceutical Sciences (APS), has co-hosted successful workshops on drug developability and has co-organised a number of APS International Pharm Sci conferences (the UK’s premier Pharm Sci event).
Tommy completed his undergraduate and postgraduate education in Pharmacy at the University of Strathclyde. Following that he undertook post doctoral study at the universities of Strathclyde and Glasgow assessing novel drug carrier systems as immunological adjuvants. He first joined Controlled Therapeutics in 1988 where he was involved in researching the use of hydrogels as novel drug delivery systems for a range of indications. In 1990 Tommy commenced his career at Pfizer Global Research and Development at Sandwich joining as a formulation scientist. Since joining Pfizer he has held a variety of positions in Pharmaceutical Research and Development in that time ultimately heading the department since 2002. Tommy has been involved in the development of a number of drug development programs and wide variety dosage form types in that time many of which are now marketed products.
Carol has over 20 years drug development, managerial and project management experience working in the biotechnology, pharmaceutical and device industries. She is a registered Pharmacist with a PhD from the University of Manchester, in controlled drug release. Her background is in pharmaceutical development and CMC regulatory affairs with scientific and technical knowledge in drug delivery combined with business and commercial skills. This she has gained from a career working for initially Fisons and then Astra Zeneca in Pharmaceutical development and project management. Moving into Programme Management with Quadrant Healthcare working with novel particle technologies and biologicals, with a range of partnering companies. She is currently a consultant, involved in a range of projects at all stages of drug development, for in house development and partnering from small start-up companies to multinational companies.
